

IN THE SPECIFICATION:

Page 1, after line 10, insert the following:

CROSS REFERENCE TO RELATED APPLICATIONS

Q1 This is the U.S. national phase application based upon International Application No. PCT/US00/16559 filed June 15, 2000, and published in English on December 21, 2000.

This application claims the benefit of priority under 35 U.S.C. § 119 based upon U.S. Provisional Application Serial No. 60/139,528 filed June 16, 1999.

The entire disclosures of the prior applications are incorporated herein by reference.

IN THE CLAIMS:

Please amend claim 32 as follows:

32. (Amended) A method of treating a disease or disorder selected from

Q2 the group consisting of chronic pain, drug abuse, schizophrenia, depression, central reward pathway, HIV infection, cardiovascular disease, and hypertension, which method comprises administering a therapeutically effective dose of a compound of claim 24.

Please add claims 33-35: